Next Article in Journal
Incidence and Predictors of Cardiac Implantable Electronic Devices Malfunction with Radiotherapy Treatment
Previous Article in Journal
Radiographic Assessment of Tibiofibular Syndesmosis Injury with Different Durations and Types of Fixation
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 11
Issue 21
10.3390/jcm11216330
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Galectin-1 and Galectin-9 Concentration in Maternal Serum: Implications in Pregnancies Complicated with Preterm Prelabor Rupture of Membranes

by
Dorota Grażyna Boroń
1,2,*,
Aleksy Świetlicki
1,
Michał Potograbski
1,
Grażyna Kurzawińska
1,3,
Przemysław Wirstlein
4,
Daniel Boroń
2,4,
Krzysztof Drews
1 and
Agnieszka Seremak-Mrozikiewicz
1
1
Department of Perinatology and Women’s Diseases, Poznań University of Medical Sciences, 60-535 Poznan, Poland
2
Doctoral School, Poznań University of Medical Sciences, 60-812 Poznan, Poland
3
Laboratory of Molecular Biology, Department of Perinatology and Women’s Diseases, Poznań University of Medical Sciences, 60-535 Poznan, Poland
4
Department of Reproduction, Poznań University of Medical Sciences, 60-535 Poznan, Poland
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2022, 11(21), 6330; https://doi.org/10.3390/jcm11216330
Original submission received: 26 September 2022 / Revised: 18 October 2022 / Accepted: 26 October 2022 / Published: 27 October 2022
(This article belongs to the Section Obstetrics & Gynecology)
Browse Figures
Versions Notes

Abstract

:
Preterm prelabor rupture of membranes (pPROM) accounts for nearly half of premature births. Although several risk factors have been identified, no markers allowing for effective prevention have been discovered. In this study, we investigated how the maternal serum levels of galectin-1 and galectin-9 change in patients with pPROM in comparison to uncomplicated pregnancies. A total of 75 patients were enrolled to both study and control group (37 vs. 38, respectively). The serum concentration of galectin-1 and galectin-9 were assayed in duplicate using an enzyme-linked immunoassay. All analyses were performed using PQ Stat v. 1.8.4 software. Galectin-1 levels were significantly higher in the controls (13.32 vs. 14.71 ng/mL, p = 0.02). Galectin-9 levels were similar in both groups (13.31 vs. 14.76 ng/mL, p = 0.30). Lower galectin levels were detected for early pPROM (before 32nd GW) in comparison to late pPROM and the controls (8.85 vs. 14.45 vs. 14.71 ng/mL, p = 0.0004). Similar trend was observed in galectin-9 levels, although no statistical significance was found (11.57 vs. 14.25 vs. 14.76 ng/mL, p = 0.26). Low galectin-1 maternal serum level is associated with the incidence of preterm prelabor rupture of membranes. Galectin-9 maternal serum levels were not significantly correlated with pPROM. However, in order to investigate gal-1 and gal-9 levels as potential, promising markers of pPROM, further clinical studies on larger groups are required.
Keywords:
galectins; pPROM; pregnancy

1. Introduction

The premature prelabor rupture of fetal membranes (pPROM) is defined as rupture of the membranes before 37 weeks of gestation unrelated to labor [1]. Affecting about 4% of pregnancies worldwide, it accounts for almost half of premature labors (PL)—a global burden, with 1 million children dying before the age of 5 years annually [2,3]. In addition to its high mortality, PL is also associated with prolonged hospital admissions, both in childhood and adult life, and, therefore, with significant costs to health systems [4,5,6,7,8,9,10]. PL is further classified as extremely preterm (<28 gestational weeks (GW)), very preterm (28 to <32 GW) and moderate (32 to <34 GW) to late preterm (34 to <37 GW), with the highest complications and mortality rate in extremely and very preterm neonates [3,11]. Despite great advances in perinatal care in recent decades, the pathophysiological mechanisms leading to pPROM remain uncertain. Several risk factors have been identified, including vaginal infection, multiple pregnancies, polyhydramnios, vaginal bleeding, or smoking [12]. The most widespread view is that pPROM is a complication caused by a preterm activation of the common pathway leading to weakening and eventually to the membranes’ rupture. Microfractures that appear on the surface are portals of entry for pathogens, which result in a possibly life-threatening intrauterine infection [13]. However, we lack specific markers, which may distinguish high-risk groups of pPROM and its most dangerous complications, which could easily be implemented in clinical practice.
Galectins, a group of proteins widely present in mammals, regulate a variety of key biological processes [14]. To date, 13 subtypes have been identified in humans [15]. Their biological function varies depending on the subtype, availability of a suitable ligand and even local concentrations, thus creating functional diversification [16,17]. Expressed in various locations at the materno-fetal site, galectins are mainly involved in immune modulation and early pregnancy events, such as embryo implantation, trophoblast invasion and angiogenesis [18,19]. Therefore, they are responsible for the physiological, healthy course of pregnancy. Due to their immunomodulating function, galectins function as a shield, preventing the rejection of the semi-allogenic fetus and, as a consequence, also enable the termination of the pregnancy [20,21,22]. As previously described in numerous pregnancy complications, including preecalmpsia [23], fetal growth restriction [24] or the premature rupture of membranes [25], the role of galectins remains unclear. The research in this field is still at an early stage and requires further exploration.
In this study, we aimed to investigate maternal serum galectin-1 and galacetin-9 levels in pregnancies complicated with pPROM in comparison to healthy pregnancies delivered at term.

2. Materials and Methods

This prospective, single-center study was conducted between June 2020 and May 2022 at the Gynecology and Obstetrics Clinical Hospital in Poznań. A total of 75 women were enrolled, including 37 cases of pPROM (between 23 and 36 weeks of gestation, healthy women with physiological course of the pregnancy beforehand), prior to the administration of any drugs routinely recommended in this clinical situation, and 38 healthy mothers of full-term infants. Cases were enrolled at the hospital’s emergency department during the initial evaluation, after confirmation of pPROM and revision of patient’s general and obstetrical history. Gestational-aged matched pregnant women, admitted to our hospital in the same period, with no obstetric complications or other serious medical conditions, were selected as the control group. Each patient provided a onetime 10 mL sample of the whole blood collected into a K2EDTA tube for further testing. Each sample was centrifuged for 10 min at 2500 rpm and the collected serum was stored at −80 °C until analysis. Exclusion criteria were defined as follows: maternal age of under 18 years, history of drug abuse or cigarette smoking, serious diseases of the mother, including: hypertension, preeclampsia, diabetes, cholestasis of pregnancy, unstable thyroid disease; intrauterine infection, multiple pregnancy, detected fetal or placental abnormalities, fetal growth restriction, cervical insufficiency. Controls were enrolled during a routine check-up of an uncomplicated pregnancy. All subjects were obliged to provide written, informed consent to participate in the study. Medical records of the participants were acquired to obtain more detailed information about the patients.
Gestational age was calculated according to the last menstrual period, or by fetal crown-rump length measurement at the first trimester. pPROM diagnosis was based on the speculum examination (visualization of amniotic fluid in the vagina) or, if necessary, by using a placental insulin growth-factor-binding protein-1 test (Amnioquick, Biosynex Swiss SA). All patients with pPROM were hospitalized and managed according to the following schedule: corticosteroids for lung maturation (if <34 GW) and prophylactic antibiotics were administered, together with a daily cardiotocographic monitoring and fetal assessment. The patients were monitored for any signs of intrauterine infection (CBC and CRP every second day or more frequently, if necessary).
The serum concentration of galectin-1 and galectin-9 were assayed in duplicate using an enzyme-linked immunoassay (ELISA) kit according to the manufacturer’s protocol (Galectin-1 and Galectin-9 Human ELISA Kit, Abcam PLC, Cambridge, UK).
All analyses were performed using PQStat Software 2022 (PQStat v.1.8.4. Poznan, Poland). The Kolmogorov–Smirnov test was used to assess the distribution of all continuous variables. The variables with normal distribution were estimated via means ± standard derivation (SD) and compared with the independent samples Student’s t-test. The Mann–Whitney U-test was used to analyze non-normally distributed variables, and the results were expressed as median and interquartile range. Categorical variables were used through frequency counts and percentage. Correlations between variables were evaluated by the Spearman’s correlation analysis for galecitin-1 and by the Pearson’s correlation analysis for galectin-9. The ANOVA Kruskal–Wallis one-way analysis of variance was used to compare three independent groups for galectin-1 (<32 GW, >32 GW, controls) and ANOVA analysis of variance for galectin-9, respectively. Statistical significance was defined as p < 0.05 with a two-tailed test.

3. Results

A prospective, case–control study was conducted, involving 75 women, including 37 cases of pPROM and 38 controls. Cases and controls were evenly matched by age. Preterm prelabor rupture of membranes was defined as rupture of membranes between the 23rd and 36th gestational week. The characteristics of the cases and controls are summarized in Table 1. With a similar BMI at blood sampling, C-section rate, female neonate rate and fetal outcomes at birth, defined by pH of the neonate, statistically significant differences were observed with regard to the gestational age at delivery and the birth weight. Surprisingly, although white blood cells (WBC) count and C-reactive protein (CRP) levels were similar, galectin-1 levels were significantly higher in the controls (13.32 vs. 14.71 ng/mL, p = 0.02, shown in Figure 1). At the same time, galectin-9 levels were similar in both groups (13.31 vs. 14.76 ng/mL, p = 0.30, shown in Figure 2).
When analyzing the same data, differentiating between early (before 32nd gestational week) and late (after 32nd gestational week) pPROM, the demographic and clinical characteristics were comparable to those described before, indicating even more significant differences in terms of galectin-1 levels. This, in turn, revealed a visible tendency: the earlier the pregnancy is affected by pPROM, the lower the galectin-1 levels (8.85 vs. 14.45 vs. 14.71 ng/mL, p = 0.0004, shown in Figure 3). A similar trend was observed in galectin-9 levels, although no statistical significance was observed (11.57 vs. 14.25 vs. 14.76 ng/mL, p = 0.26, shown in Figure 4). More detailed data regarding the characteristics with a distinction for early and late pPROM are presented in Table 2.
In order to further investigate the association between pPROM and galectin-1 and 9 levels, the correlations between galectins and other parameters were analyzed (Table 3). Galectin-1 levels were positively correlated with the gestational age at delivery and the birth weight (r = 0.33, p = 0.007 and r = 0.32, p = 0.008, respectively), whereas galectin-9 levels were significantly related to the BMI of the mother (r = 0.34, p = 0.003).

4. Discussion

The objective of this study was to investigate the maternal serum levels of galectin-1 and galectin-9 in pregnancies complicated with pPROM. We hypothesized that the maternal serum levels of galectin-1 and galectin-9 would decrease in pregnancies with pPROM, as they both serve as anti-inflammatory molecules, allowing for the maintenance of pregnancy [26,27]. In accordance with our hypothesis, galectin-1 levels were found to be significantly lower in pregnancies with pPROM compared with the control group, especially for early pPROM (<32 GW), which often results in extremely or very preterm labor, which has a huge impact on future care in childhood and adult life. We also found a similar pattern for galectin-9, but with no statistical significance.
Galectin-1 function was widely described in the literature due to its multidirectional effect on all stages of pregnancy. Galectin-1 expression, which is involved in the processes which enable trophoblast attachment to the uterine epithelium [28], is observed in a few-days-old human embryo. Most abundantly expressed in the decidual stromal cells and fetal trophoblasts, gal-1 is sex-hormone-dependent, and thus continuously produced throughout the pregnancy [29]. For instance, galectin-1 is responsible for shaping the phenotype of leukocytes through decidual NK (dNK) cells [30], inducing apoptosis of activated decidual T cells [31] and, thus, ensuring homeostasis at the maternal–fetal interface [15,32]. As maternal serum gal-1 levels significantly increase over the course of pregnancy, it has been suggested as a biomarker for miscarriage, preeclampsia or HELLP syndrome. Nevertheless, none of the previous findings were further implemented in the clinical practice. To the best of our knowledge, only one study investigated the association between serum levels of galectin-1 and pPROM [28] However, Kaya et al., obtained contrasting results, in comparison to ours, demonstrating higher concentrations of gal-1 in patients with pPROM, which is not self-explanatory regardingthe mechanisms of expression of gal-1. Importantly, gal-1 inhibits IL-6 in decidual cells [27], which would account for its anti-inflammatory action, allowing for a favorable microenvironment for maintaining the pregnancy. Additionally, gal-1 expression decreases at term, facilitating the pro-inflammatory changes that lead to the onset of labor [33]. In our study, we hypothesized that maternal serum concentration reflects the expression of gal-1 at the materno-fetal site. Considering the abovementioned reports and our findings, in which we demonstrated that the gal-1 concentration is significantly decreased in patients with pPROM in comparison to the gestational-age-matched controls, this hypothesis may be accurate, suggesting that the presence of galectins in the maternal circulation constitutes a consequence of leakage from the placental tissue. Nevertheless, to fully substantiate this thesis, more detailed studies are essential, involving the placental expression of gal-1 together with serum concentration.
To date, Galectin-9 has been less known, and the data regarding its exact function and characteristics are scarce. Apart from the endometrium, trophoblasts and stromal cells of the decidua [19,34], gal-9 is also expressed by the endothelial cells of the placenta and several types of immune cells [26,35]. Similarly to gal-1, in a murine model gal-9 participates in the processes involved in local anti-inflammatory environment, enabling implantation and early fetal development [34]. Moreover, gal-9 accounts also for the suppression of uterine NK cells by means of secretion in the endometrial stromal cells [26]. Nevertheless, the available data are only based on a murine model, although a similar role for gal-9 has been proposed in view of human pregnancy. As the pregnancy progresses, both the expression and concentration levels of gal-9 in the maternal blood increases, rendering it another possibly crucial galectin in the maintenance of pregnancy [36]. In terms of the available data concerning pregnancy complications, several studies have suggested the role of low gal-9 expression and/or maternal serum levels in spontaneous abortions [26], recurrent pregnancy loss [37,38] and preeclampsia [39,40]. Interestingly, some studies have indicated that levels of gal-9 serum level is higher in women carrying a male fetus, as compared to a female fetus [41,42]. Furthermore, as far as pPROM is concerned, gal-9 expression in the chorion is reduced at the site of the membrane weakening, resulting in rupture. In contrast, to our knowledge, the serum levels of gal-9 in pPROM have not been investigated to date. Despite their having a similar hypothesis as gal-1, we did not confirm a significant difference in gal-9 serum levels in maternal serum in pPROM patients as compared to the healthy controls, even when differentiated into the early and late preterm membrane rupture.
This study has several limitations, which mainly include the small number of participants and single-center character. Additionally, the examination of placenta and fetal membranes may constitute an additional asset in the future.
To conclude, low galectin-1 maternal serum level is associated with the incidence of preterm prelabor rupture of membranes (especially before the 32nd gestational week), either as a trigger factor or one of the molecules on the cascade of events leading to fetal membranes’ damage. Conversely, galectin-9 maternal serum levels are most probably not significantly associated with incidence of pPROM. However, to investigate gal-1 and gal-9 levels as potential, promising clinical markers for the prediction of pPROM, further clinical studies on larger groups are required.

Author Contributions

Conceptualization, D.B. (Dorota Boroń) and A.S.-M.; methodology, D.B. (Dorota Boroń); software, D.B. (Daniel Boroń); validation, A.Ś., M.P. and G.K.; formal analysis, D.B. (Dorota Boroń) and P.W.; investigation, D.B. (Dorota Boroń), A.Ś. and M.P.; resources, D.B. (Dorota Boroń), A.Ś. and M.P.; data curation, D.B. (Dorota Boroń) and D.B. (Daniel Boroń); writing—original draft preparation, D.B. (Dorota Boroń); writing—review and editing, A.S.-M.; visualization, D.B. (Dorota Boroń) and D.B. (Daniel Boroń); supervision, A.S.-M. and K.D.; project administration, D.B. (Dorota Boroń); funding acquisition, D.B. (Dorota Boroń). All authors have read and agreed to the published version of the manuscript.

Funding

Research was financed from the large research grant from statutory funding for young researchers—doctoral students for 2021 (Poznan University of Medical Sciences: SDUM-GB25/03/21).

Institutional Review Board Statement

This study was approved by the Bioethics Committee of Poznan University of Medical Sciences, Poland, approval number 1158/19.

Informed Consent Statement

All participants were voluntary recruited and provided written informed consent before taking part in this research.

Data Availability Statement

All data generated or analyzed during this study are included in this article. Further enquiries can be directed to the corresponding author.

Conflicts of Interest

The authors have no conflict of interest to declare.

References

  1. Goldenberg, R.L.; Culhane, J.F.; Iams, J.D.; Romero, R. Epidemiology and Causes of Preterm Birth. Lancet 2008, 371, 75–84. [Google Scholar] [CrossRef]
  2. Mercer, B.M.; Crouse, D.T.; Goldenberg, R.L.; Miodovnik, M.; Mapp, D.C.; Meis, P.J.; Dombrowski, M.P. Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network the Antibiotic Treatment of PPROM Study: Systemic Maternal and Fetal Markers and Perinatal Outcomes. Am. J. Obstet. Gynecol. 2012, 206, 145.e1–145.e9. [Google Scholar] [CrossRef] [PubMed][Green Version]
  3. Walani, S.R. Global Burden of Preterm Birth. Int. J. Gynaecol. Obstet. 2020, 150, 31–33. [Google Scholar] [CrossRef] [PubMed]
  4. De Costa, A.; Moller, A.-B.; Blencowe, H.; Johansson, E.W.; Hussain-Alkhateeb, L.; Ohuma, E.O.; Okwaraji, Y.B.; Cresswell, J.; Requejo, J.H.; Bahl, R.; et al. Study Protocol for WHO and UNICEF Estimates of Global, Regional, and National Preterm Birth Rates for 2010 to 2019. PLoS ONE 2021, 16, e0258751. [Google Scholar] [CrossRef]
  5. Bérard, A.; Le Tiec, M.; De Vera, M.A. Study of the Costs and Morbidities of Late-Preterm Birth. Arch. Dis. Child. Fetal. Neonatal. Ed. 2012, 97, F329–F334. [Google Scholar] [CrossRef]
  6. Petrou, S.; Abangma, G.; Johnson, S.; Wolke, D.; Marlow, N. Costs and Health Utilities Associated with Extremely Preterm Birth: Evidence from the EPICure Study. Value Health 2009, 12, 1124–1134. [Google Scholar] [CrossRef][Green Version]
  7. O’Connor, A.R.; Wilson, C.M.; Fielder, A.R. Ophthalmological Problems Associated with Preterm Birth. Eye 2007, 21, 1254–1260. [Google Scholar] [CrossRef][Green Version]
  8. de Araújo, B.F.; Zatti, H.; Madi, J.M.; Coelho, M.B.; Olmi, F.B.; Canabarro, C.T. Analysis of Neonatal Morbidity and Mortality in Late-Preterm Newborn Infants. J. Pediatr. 2012, 88, 259–266. [Google Scholar] [CrossRef][Green Version]
  9. Saigal, S.; Doyle, L.W. An Overview of Mortality and Sequelae of Preterm Birth from Infancy to Adulthood. Lancet 2008, 371, 261–269. [Google Scholar] [CrossRef]
  10. Ramenghi, L.A. Late Preterm Babies and the Risk of Neurological Damage. Acta Biomed. 2015, 86 (Suppl. S1), 36–40. [Google Scholar]
  11. Preterm Birth. Available online: https://www.who.int/news-room/fact-sheets/detail/preterm-birth (accessed on 13 October 2022).
  12. Silverman, R.K.; Wojtowycz, M. Risk Factors in Premature Rupture of Membranes. Prim. Care Update Ob. Gyns. 1998, 5, 181. [Google Scholar] [CrossRef]
  13. Richardson, L.S.; Vargas, G.; Brown, T.; Ochoa, L.; Sheller-Miller, S.; Saade, G.R.; Taylor, R.N.; Menon, R. Discovery and Characterization of Human Amniochorionic Membrane Microfractures. Am. J. Pathol. 2017, 187, 2821–2830. [Google Scholar] [CrossRef] [PubMed][Green Version]
  14. Gabius, H.-J.; André, S.; Kaltner, H.; Siebert, H.-C. The Sugar Code: Functional Lectinomics. Biochim. Biophys. Acta 2002, 1572, 165–177. [Google Scholar] [CrossRef]
  15. Than, N.G.; Romero, R.; Goodman, M.; Weckle, A.; Xing, J.; Dong, Z.; Xu, Y.; Tarquini, F.; Szilagyi, A.; Gal, P.; et al. A Primate Subfamily of Galectins Expressed at the Maternal-Fetal Interface That Promote Immune Cell Death. Proc. Natl. Acad. Sci. USA 2009, 106, 9731–9736. [Google Scholar] [CrossRef] [PubMed][Green Version]
  16. Vasta, G.R. Roles of Galectins in Infection. Nat. Rev. Microbiol. 2009, 7, 424–438. [Google Scholar] [CrossRef] [PubMed][Green Version]
  17. Cooper, D.N.W. Galectinomics: Finding Themes in Complexity. Biochim. Biophys. Acta 2002, 1572, 209–231. [Google Scholar] [CrossRef]
  18. Sano, H.; Hsu, D.K.; Apgar, J.R.; Yu, L.; Sharma, B.B.; Kuwabara, I.; Izui, S.; Liu, F.-T. Critical Role of Galectin-3 in Phagocytosis by Macrophages. J. Clin. Invest. 2003, 112, 389–397. [Google Scholar] [CrossRef][Green Version]
  19. von Wolff, M.; Wang, X.; Gabius, H.-J.; Strowitzki, T. Galectin Fingerprinting in Human Endometrium and Decidua during the Menstrual Cycle and in Early Gestation. Mol. Hum. Reprod. 2005, 11, 189–194. [Google Scholar] [CrossRef][Green Version]
  20. Than, N.G.; Romero, R.; Balogh, A.; Karpati, E.; Mastrolia, S.A.; Staretz-Chacham, O.; Hahn, S.; Erez, O.; Papp, Z.; Kim, C.J. Galectins: Double-Edged Swords in the Cross-Roads of Pregnancy Complications and Female Reproductive Tract Inflammation and Neoplasia. J. Pathol. Transl. Med. 2015, 49, 181–208. [Google Scholar] [CrossRef][Green Version]
  21. Vasta, G.R.; Ahmed, H.; Nita-Lazar, M.; Banerjee, A.; Pasek, M.; Shridhar, S.; Guha, P.; Fernández-Robledo, J.A. Galectins as Self/Non-Self Recognition Receptors in Innate and Adaptive Immunity: An Unresolved Paradox. Front. Immunol. 2012, 3, 199. [Google Scholar] [CrossRef][Green Version]
  22. Rabinovich, G.A.; Toscano, M.A. Turning “sweet” on Immunity: Galectin-Glycan Interactions in Immune Tolerance and Inflammation. Nat. Rev. Immunol. 2009, 9, 338–352. [Google Scholar] [CrossRef] [PubMed]
  23. Shankar, R.; Johnson, M.P.; Williamson, N.A.; Cullinane, F.; Purcell, A.W.; Moses, E.K.; Brennecke, S.P. Molecular Markers of Preterm Labor in the Choriodecidua. Reprod. Sci. 2010, 17, 297–310. [Google Scholar] [CrossRef] [PubMed][Green Version]
  24. Boutsikou, T.; Giotaki, M.; Boutsikou, M.; Briana, D.D.; Baka, S.; Piatopoulou, D.; Hassiakos, D.; Gourgiotis, D.; Malamitsi-Puchner, A. Cord Blood Galectin-1 and -3 Concentrations in Term Pregnancies with Normal Restricted and Increased Fetal Growth. J. Perinat. Med. 2015, 43, 305–309. [Google Scholar] [CrossRef] [PubMed]
  25. Than, N.G.; Kim, S.-S.; Abbas, A.; Han, Y.M.; Hotra, J.; Tarca, A.L.; Erez, O.; Wildman, D.E.; Kusanovic, J.P.; Pineles, B.; et al. Chorioamnionitis and Increased Galectin-1 Expression in PPROM—An Anti-Inflammatory Response in the Fetal Membranes? Am. J. Reprod. Immunol. 2008, 60, 298–311. [Google Scholar] [CrossRef] [PubMed][Green Version]
  26. Heusschen, R.; Freitag, N.; Tirado-González, I.; Barrientos, G.; Moschansky, P.; Muñoz-Fernández, R.; Leno-Durán, E.; Klapp, B.F.; Thijssen, V.L.J.L.; Blois, S.M. Profiling Lgals9 Splice Variant Expression at the Fetal-Maternal Interface: Implications in Normal and Pathological Human Pregnancy. Biol. Reprod. 2013, 88, 22. [Google Scholar] [CrossRef]
  27. Gómez-Chávez, F.; Castro-Leyva, V.; Espejel-Núñez, A.; Zamora-Mendoza, R.G.; Rosas-Vargas, H.; Cancino-Díaz, J.C.; Cancino-Díaz, M.E.; Estrada-Gutierrez, G.; Rodríguez-Martínez, S. Galectin-1 Reduced the Effect of LPS on the IL-6 Production in Decidual Cells by Inhibiting LPS on the Stimulation of IκBζ. J. Reprod. Immunol. 2015, 112, 46–52. [Google Scholar] [CrossRef]
  28. Tirado-González, I.; Freitag, N.; Barrientos, G.; Shaikly, V.; Nagaeva, O.; Strand, M.; Kjellberg, L.; Klapp, B.F.; Mincheva-Nilsson, L.; Cohen, M.; et al. Galectin-1 Influences Trophoblast Immune Evasion and Emerges as a Predictive Factor for the Outcome of Pregnancy. Mol. Hum. Reprod. 2013, 19, 43–53. [Google Scholar] [CrossRef][Green Version]
  29. Mulac-Jeričević, B.; Šućurović, S.; Gulic, T.; Szekeres-Bartho, J. The Involvement of the Progesterone Receptor in PIBF and Gal-1 Expression in the Mouse Endometrium. Am. J. Reprod. Immunol. 2019, 81, e13104. [Google Scholar] [CrossRef][Green Version]
  30. Sanguansermsri, D.; Pongcharoen, S. Pregnancy Immunology: Decidual Immune Cells. Asian Pac. J. Allergy Immunol. 2008, 26, 171–181. [Google Scholar]
  31. Kopcow, H.D.; Rosetti, F.; Leung, Y.; Allan, D.S.J.; Kutok, J.L.; Strominger, J.L. T Cell Apoptosis at the Maternal-Fetal Interface in Early Human Pregnancy, Involvement of Galectin-1. Proc. Natl. Acad. Sci. USA 2008, 105, 18472–18477. [Google Scholar] [CrossRef][Green Version]
  32. Than, N.G.; Romero, R.; Kim, C.J.; McGowen, M.R.; Papp, Z.; Wildman, D.E. Galectins: Guardians of Eutherian Pregnancy at the Maternal-Fetal Interface. Trends Endocrinol. Metab. 2012, 23, 23–31. [Google Scholar] [CrossRef][Green Version]
  33. El-Azzamy, H.; Balogh, A.; Romero, R.; Xu, Y.; LaJeunesse, C.; Plazyo, O.; Xu, Z.; Price, T.G.; Dong, Z.; Tarca, A.L.; et al. Characteristic Changes in Decidual Gene Expression Signature in Spontaneous Term Parturition. J. Pathol. Transl. Med. 2017, 51, 264–283. [Google Scholar] [CrossRef] [PubMed]
  34. Shimizu, Y.; Kabir-Salmani, M.; Azadbakht, M.; Sugihara, K.; Sakai, K.; Iwashita, M. Expression and Localization of Galectin-9 in the Human Uterodome. Endocr. J. 2008, 55, 879–887. [Google Scholar] [CrossRef] [PubMed][Green Version]
  35. Li, Y.; Feng, J.; Geng, S.; Geng, S.; Wei, H.; Chen, G.; Li, X.; Wang, L.; Wang, R.; Peng, H.; et al. The N- and C-Terminal Carbohydrate Recognition Domains of Galectin-9 Contribute Differently to Its Multiple Functions in Innate Immunity and Adaptive Immunity. Mol. Immunol. 2011, 48, 670–677. [Google Scholar] [CrossRef] [PubMed]
  36. Meggyes, M.; Miko, E.; Polgar, B.; Bogar, B.; Farkas, B.; Illes, Z.; Szereday, L. Peripheral Blood TIM-3 Positive NK and CD8+ T Cells throughout Pregnancy: TIM-3/Galectin-9 Interaction and Its Possible Role during Pregnancy. PLoS ONE 2014, 9, e92371. [Google Scholar] [CrossRef][Green Version]
  37. Wu, M.; Zhu, Y.; Zhao, J.; Ai, H.; Gong, Q.; Zhang, J.; Zhao, J.; Wang, Q.; La, X.; Ding, J. Soluble Costimulatory Molecule STim3 Regulates the Differentiation of Th1 and Th2 in Patients with Unexplained Recurrent Spontaneous Abortion. Int. J. Clin. Exp. Med. 2015, 8, 8812–8819. [Google Scholar]
  38. Wyatt, M.A.; Baumgarten, S.C.; Weaver, A.L.; Van Oort, C.C.; Fedyshyn, B.; Ruano, R.; Shenoy, C.C.; Enninga, E.A.L. Evaluating Markers of Immune Tolerance and Angiogenesis in Maternal Blood for an Association with Risk of Pregnancy Loss. J. Clin. Med. 2021, 10, 3579. [Google Scholar] [CrossRef]
  39. Miko, E.; Meggyes, M.; Bogar, B.; Schmitz, N.; Barakonyi, A.; Varnagy, A.; Farkas, B.; Tamas, P.; Bodis, J.; Szekeres-Bartho, J.; et al. Involvement of Galectin-9/TIM-3 Pathway in the Systemic Inflammatory Response in Early-Onset Preeclampsia. PLoS ONE 2013, 8, e71811. [Google Scholar] [CrossRef]
  40. Hao, H.; He, M.; Li, J.; Zhou, Y.; Dang, J.; Li, F.; Yang, M.; Deng, D. Upregulation of the Tim-3/Gal-9 Pathway and Correlation with the Development of Preeclampsia. Eur. J. Obstet. Gynecol. Reprod. Biol. 2015, 194, 85–91. [Google Scholar] [CrossRef]
  41. Enninga, E.A.L.; Nevala, W.K.; Creedon, D.J.; Markovic, S.N.; Holtan, S.G. Fetal Sex-Based Differences in Maternal Hormones, Angiogenic Factors, and Immune Mediators During Pregnancy and the Postpartum Period. Am. J. Reprod. Immunol. 2015, 73, 251–262. [Google Scholar] [CrossRef][Green Version]
  42. Enninga, E.A.L.; Harrington, S.M.; Creedon, D.J.; Ruano, R.; Markovic, S.N.; Dong, H.; Dronca, R.S. Immune Checkpoint Molecules Soluble Program Death Ligand 1 and Galectin-9 Are Increased in Pregnancy. Am. J. Reprod. Immunol. 2018, 79. [Google Scholar] [CrossRef] [PubMed]
Jcm 11 06330 g001 550
Figure 1. Distribution for maternal serum galectin-1 levels in study vs. control group.
Figure 1. Distribution for maternal serum galectin-1 levels in study vs. control group.
Jcm 11 06330 g001
Jcm 11 06330 g002 550
Figure 2. Distribution for maternal serum galectin-9 levels in study vs. control group.
Figure 2. Distribution for maternal serum galectin-9 levels in study vs. control group.
Jcm 11 06330 g002
Jcm 11 06330 g003 550
Figure 3. Comparison of three independent groups for galectin-1.
Figure 3. Comparison of three independent groups for galectin-1.
Jcm 11 06330 g003
Jcm 11 06330 g004 550
Figure 4. Comparison of three independent groups for galectin-9.
Figure 4. Comparison of three independent groups for galectin-9.
Jcm 11 06330 g004
Table
Table 1. Demographic and clinical characteristics of the study population.
Table 1. Demographic and clinical characteristics of the study population.
pPROM (n = 37)Control (n = 38)p Value
Age (years)31.62 ± 5.1228.95 ± 6.260.05
Gravida *220.11
BMI at blood sampling (kg/m2)26.13 ± 4.0426.56 ± 4.6260.67
GA at blood sampling32.30 ± 3.0830.29 ± 3.270.008
GA at delivery34.43 ± 2.7238.47 ± 1.14<0.00001
C-section (%) **35.1426.670.46
Female neonate (%) **35.14500.22
Birth weight (g)2407.97 ± 575.353456.50 ± 383.94<0.000001
pH of the neonate at birth7.27 ± 0.087.27 ± 0.060.65
WBC count12.59 ± 3.1110.81 ± 2.350.08
CRP5.76 ± 6.805.91± 2.970.80
Galectin-1 (ng/mL) *13.32 (6.29)14.71 (10.34)0.02
Galectin-9 (ng/mL)13.307 ± 4.0914.76 ± 7.470.30
pPROM—preterm prelabour rupture of membranes; GA—gestational age; BMI—body mass index; WBC—white blood cells; CRP—C-reactive protein. * Non-normally distributed values shown as median (interquartile range). ** Categorical variables shown as percentage. Bold font indicates statistical significance.
Table
Table 2. Demographic and clinical characteristics with distinction for early (<32 GW) and late (>32 GW) pPROM.
Table 2. Demographic and clinical characteristics with distinction for early (<32 GW) and late (>32 GW) pPROM.
pPROM < 32 (n = 13)pPROM > 32 (n = 24)Control (n = 38)p Value
Age (years)31.69 ± 3.3331.58 ± 5.9428.95 ± 6.260.14
Gravida *2220.11
BMI at blood sampling (kg/m2)25.73 ± 4.2926.34 ± 3.9826.56 ± 4.630.84
GA at blood sampling28.85 ± 2.4434.17 ± 1.1730.29 ± 3.27<0.000001
GA at delivery33.08 ± 3.6835.17 ± 1.7138.47 ± 1.14<0.000001
C-section (%) **38.4631.5326.670.15
Female neonate (%) **30.7738.12500.45
Birth weight (g)2185.38 ± 754.982528.54 ± 421.393456.50 ± 383.94<0.000001
pH of the neonate at birth7.26 ± 0.077.8 ± 0.067.27 ± 0.060.84
WBC count13.34 ± 3.2412.18 ± 3.0310.81 ± 2.350.11
CRP7.19 ± 6.874.98 ± 6.785.19 ± 2.970.57
Galectin-1 (ng/mL) *8.85 (3.54)14.45 (5.14)14.71 (10.34)0.0004
Galectin-9 (ng/mL)11.57 ± 3.4214.25 ± 4.1814.76 ± 7.470.26
GW—gestational week; pPROM—preterm prelabour rupture of membranes; GA—gestational age; BMI—body mass index; WBC—white blood cells; CRP—C-reactive protein. * Non-normally distributed values shown as median (interquartile range). ** Categorical variables shown as percentage. Bold font indicates statistical significance.
Table
Table 3. Correlactions between galectins levels and other parameters. Spearman’s correlation analysis was used for galectin-1 and Pearson’s correlation analysis for galectin-9.
Table 3. Correlactions between galectins levels and other parameters. Spearman’s correlation analysis was used for galectin-1 and Pearson’s correlation analysis for galectin-9.
Galectin-1Galectin-9
AgeR = 0.18R = −0.03
p = 0.12p = 0.80
BMIR = 0.11R = 0.34
p = 0.33p = 0.003
GA at blood samplingR = 0.15R = 0.08
p = 0.19p = 0.52
GA at deliveryR = 0.33R = 0.17
p = 0.007p = 0.15
Birth weightR = 0.32R = 0.09
p = 0.008p = 0.49
pH of the neonate at birthR = −0.11R = 0.14
p = 0.38p = 0.25
WBCR = −0.25R = 0.04
p = 0.09p = 0.79
CRPR = 0.33R = 0.04
p = 0.82p = 0.79
GA—gestational age; BMI—body mass index; WBC—white blood cells; CRP—C-reactive protein. Bold font indicates statistical significance.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Boroń, D.G.; Świetlicki, A.; Potograbski, M.; Kurzawińska, G.; Wirstlein, P.; Boroń, D.; Drews, K.; Seremak-Mrozikiewicz, A. Galectin-1 and Galectin-9 Concentration in Maternal Serum: Implications in Pregnancies Complicated with Preterm Prelabor Rupture of Membranes. J. Clin. Med. 2022, 11, 6330. https://doi.org/10.3390/jcm11216330

AMA Style

Boroń DG, Świetlicki A, Potograbski M, Kurzawińska G, Wirstlein P, Boroń D, Drews K, Seremak-Mrozikiewicz A. Galectin-1 and Galectin-9 Concentration in Maternal Serum: Implications in Pregnancies Complicated with Preterm Prelabor Rupture of Membranes. Journal of Clinical Medicine. 2022; 11(21):6330. https://doi.org/10.3390/jcm11216330

Chicago/Turabian Style

Boroń, Dorota Grażyna, Aleksy Świetlicki, Michał Potograbski, Grażyna Kurzawińska, Przemysław Wirstlein, Daniel Boroń, Krzysztof Drews, and Agnieszka Seremak-Mrozikiewicz. 2022. "Galectin-1 and Galectin-9 Concentration in Maternal Serum: Implications in Pregnancies Complicated with Preterm Prelabor Rupture of Membranes" Journal of Clinical Medicine 11, no. 21: 6330. https://doi.org/10.3390/jcm11216330

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop